Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours

被引:56
作者
Finberg, JPM
Youdim, MBH
机构
[1] Technion Israel Inst Technol, Rappaport Family Fac Med, Dept Pharmacol, Haifa, Israel
[2] Technion Israel Inst Technol, Eve Topf & Natl Parkinson Fdn, Ctr Neurodegenerat, Rappaport Family Fac Med, Haifa, Israel
关键词
rasagiline; selegiline; monoamine oxidase A and B inhibitors; dopamine; serotonin; noradrenaline; tyramine; Parkinson's disease;
D O I
10.1016/S0028-3908(02)00216-2
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Rasagiline [N-propargyl-IR(+)-aminoindan; TVP1012] is a potent irreversible monoamine oxidase (MAO) inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease. In this study we examined effects of rasagiline on CNS monoamine levels, modification of behavioural response to L-tryptophan, fluoxetine and L-DOPA, and reversal of reserpine syndrome. Reserpine-induced ptosis was reversed by rasagiline at doses above 2 mg.kg(-1) i.p., which inhibit MAO-A as well as MAO-B, but not at MAO-B-selective doses. However, combination of rasagiline (10 mg.kg(-1) i.p.) with L-DOPA or L-tryptophan (50 mg.kg(-1) i.p.), or rasagiline (10 mg.kg(-1) p.o.) with fluoxetine (10 mg.kg(-1) p.o.), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both MAO-A and MAO-B by tranylcypromine together with the monoamine precursors. Following oral administration, levels of noradrenaline (NA), 5-hydroxytryptamine (5-HT) and dopamine (DA) were unaffected in hippocampus and striatum after single doses of rasagiline up to 2 mg.kg(-1). Following chronic oral administration (21 days, one dose daily), levels of NA, 5-HT and DA in hippocampus and striatum were unaffected by rasagiline at doses up to I mg.kg(-1). Rasagiline does not modify CNS monoamine tissue levels or monoamine-induced behavioural syndromes at doses which selectively inhibit MAO-B but not MAO-A. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1110 / 1118
页数:9
相关论文
共 43 条
[1]   BEHAVIORAL HYPERACTIVITY IN RATS TREATED WITH SELECTIVE MONOAMINE-OXIDASE INHIBITORS AND LM-5008, A SELECTIVE 5-HYDROXYTRYPTAMINE UPTAKE BLOCKER [J].
ASHKENAZI, R ;
FINBERG, JPM ;
YOUDIM, MBH .
BRITISH JOURNAL OF PHARMACOLOGY, 1983, 79 (03) :765-770
[2]   POTENTIATION OF ANTI AKINETIC EFFECT AFTER L-DOPA TREATMENT BY AN INHIBITOR OF MAO-B, DEPRENIL [J].
BIRKMAYER, W ;
RIEDERER, P ;
YOUDIM, MBH ;
LINAUER, W .
JOURNAL OF NEURAL TRANSMISSION, 1975, 36 (3-4) :303-326
[3]  
BIRKMAYER W, 1977, LANCET, V1, P439
[4]   EFFECTS OF CHRONIC REGIMENS OF CLORGYLINE AND PARGYLINE ON MONO-AMINE METABOLISM IN THE RAT-BRAIN [J].
CAMPBELL, IC ;
ROBINSON, DS ;
LOVENBERG, W ;
MURPHY, DL .
JOURNAL OF NEUROCHEMISTRY, 1979, 32 (01) :49-55
[5]   Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease [J].
Churchyard, A ;
Mathias, CJ ;
Boonkongchuen, P ;
Lees, AJ .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1997, 63 (02) :228-234
[6]   DEPRENYL IN PARKINSON DISEASE [J].
EISLER, T ;
TERAVAINEN, H ;
NELSON, R ;
KREBS, H ;
WEISE, V ;
LAKE, CR ;
EBERT, MH ;
WHETZEL, N ;
MURPHY, DL ;
KOPIN, IJ ;
CALNE, DB .
NEUROLOGY, 1981, 31 (01) :19-23
[7]  
Finberg J P, 1999, Adv Neurol, V80, P495
[8]  
Finberg JPM, 1996, J NEURAL TRANSM-SUPP, P95
[9]  
Finberg JPM, 1998, NEUROREPORT, V9, P703
[10]  
FINBERG JPM, 1995, J NEUROCHEM, V65, P1213